




Searching News Database: hematopoietic stem cell
HSMN NewsFeed - 22 Nov 2024
U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE(TM) Cord Blood Cell Therapy Product
U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE(TM) Cord Blood Cell Therapy Product
HSMN NewsFeed - 13 Jun 2022
STRM.BIO Appoints Vanessa Salazar as Vice President of Business Development
STRM.BIO Appoints Vanessa Salazar as Vice President of Business Development
HSMN NewsFeed - 13 Jul 2021
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
HSMN NewsFeed - 11 May 2021
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
HSMN NewsFeed - 18 Sep 2020
BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020
BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020
HSMN NewsFeed - 7 Jan 2020
IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer
IFM Therapeutics Appoints Michael Cooke, Ph.D., as Chief Scientific Officer
HSMN NewsFeed - 6 Jan 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
HSMN NewsFeed - 16 Jan 2018
RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
HSMN NewsFeed - 28 Aug 2017
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
HSMN NewsFeed - 26 Oct 2016
Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth
Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth
HSMN NewsFeed - 25 May 2016
Roche announces the first FDA-approved CMV test for use in hematopoietic stem cell transplant recipients
Roche announces the first FDA-approved CMV test for use in hematopoietic stem cell transplant recipients
HSMN NewsFeed - 29 Oct 2015
Bellicum Appoints Alan K. Smith as Senior Vice President of Manufacturing
Bellicum Appoints Alan K. Smith as Senior Vice President of Manufacturing
HSMN NewsFeed - 22 Sep 2015
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
ImmunoCellular Therapeutics Appoints Mark A. Schlossberg and Gregg A. Lapointe to its Board of Directors
HSMN NewsFeed - 15 Jul 2015
Fate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research
Fate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research
HSMN NewsFeed - 13 May 2015
Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical Development
Jeng-Dar Yang Ph.D. Joins Actinium Pharmaceuticals as Vice President of Pharmaceutical Development
HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
HSMN NewsFeed - 18 Nov 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
HSMN NewsFeed - 22 Oct 2013
Gentium Receives Marketing Authorization From the European Commission for Defitelio(R) (Defibrotide)
Gentium Receives Marketing Authorization From the European Commission for Defitelio(R) (Defibrotide)
HSMN NewsFeed - 21 Feb 2013
Gentium Provides Update on the Review of Defibrotide Marketing Authorization
Gentium Provides Update on the Review of Defibrotide Marketing Authorization
HSMN NewsFeed - 13 Feb 2013
Cellerant Appoints William Reed, M.D., as Vice President, Clinical Development
Cellerant Appoints William Reed, M.D., as Vice President, Clinical Development
HSMN NewsFeed - 15 Oct 2012
Fate Therapeutics Appoints Christian Weyer As President And Chief Executive Officer
Fate Therapeutics Appoints Christian Weyer As President And Chief Executive Officer
HSMN NewsFeed - 5 Sep 2012
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
HSMN NewsFeed - 16 Nov 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
HSMN NewsFeed - 8 Sep 2009
Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
HSMN NewsFeed - 16 Jun 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
HSMN NewsFeed - 13 Feb 2009
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
HSMN NewsFeed - 9 Feb 2009
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
HSMN NewsFeed - 15 Jan 2009
Osiris Receives FDA Clearance to Broaden Prochymal Expanded Access Program
Osiris Receives FDA Clearance to Broaden Prochymal Expanded Access Program
HSMN NewsFeed - 8 Jan 2008
Pluristem Announces Second Clinical Indication Revascularization Effect After PLX-PAD Therapy
Pluristem Announces Second Clinical Indication Revascularization Effect After PLX-PAD Therapy
HSMN NewsFeed - 9 Oct 2007
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
HSMN NewsFeed - 18 Sep 2007
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
HSMN NewsFeed - 19 Jul 2007
Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin's Lymphoma Meets Primary Endpoint
Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin's Lymphoma Meets Primary Endpoint
HSMN NewsFeed - 5 Jul 2007
ViroPharma Initiates Phase 3 Study of CAMVIA(TM) (maribavir) in Liver Transplant Patients
ViroPharma Initiates Phase 3 Study of CAMVIA(TM) (maribavir) in Liver Transplant Patients
HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
HSMN NewsFeed - 1 May 2007
ViroPharma Announces Decision To Develop And Commercialize Maribavir In Europe
ViroPharma Announces Decision To Develop And Commercialize Maribavir In Europe
HSMN NewsFeed - 31 Jan 2007
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
HSMN NewsFeed - 12 Jan 2007
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
Astellas Pharma US, Inc. Announces Availability of MYCAMINE(R) 100mg Vial
HSMN NewsFeed - 26 Dec 2006
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
Astellas Pharma US, Inc. Submits Supplemental New Drug Application For Antifungal Product MYCAMINE(R)
HSMN NewsFeed - 28 Nov 2006
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
HSMN NewsFeed - 7 Nov 2006
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
HSMN NewsFeed - 2 Nov 2006
Enzon Pharmaceuticals Announces Second Investigational New Drug Application Approved for Novel rhMBL
Enzon Pharmaceuticals Announces Second Investigational New Drug Application Approved for Novel rhMBL
HSMN NewsFeed - 10 Oct 2006
Genzyme Announces Proposal to Increase Its Offer to Acquire AnorMED to $13.50 Per Share in Cash
Genzyme Announces Proposal to Increase Its Offer to Acquire AnorMED to $13.50 Per Share in Cash
HSMN NewsFeed - 28 Sep 2006
ViroPharma Initiates First of Two Phase 3 Studies of Maribavir in Transplant Patients
ViroPharma Initiates First of Two Phase 3 Studies of Maribavir in Transplant Patients
HSMN NewsFeed - 22 Sep 2006
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
HSMN NewsFeed - 31 May 2006
ThermoGenesis & NETCORD Note U.S. Patent Office's Rejection of PharmaStem Cord Blood Stem Cell Patent Claims
ThermoGenesis & NETCORD Note U.S. Patent Office's Rejection of PharmaStem Cord Blood Stem Cell Patent Claims
Additional items found! 42

Members Archive contains
42 additional stories matching:
hematopoietic stem cell
(Password required)
hematopoietic stem cell
(Password required)